Support teaching, research, and patient care.
Dr. Namjoshi supports children and adults with intestinal failure on & off home parenteral nutrition (PN). Her research interests include equity and long term outcomes for people on home PN, iron in gastrointestinal diseases, clinical pathologic correlates in intestinal failure, quality of life & nutrition for patients with intestinal pseudoobstruction, and the assessment & treatment of congenital enteropathies.
1. The mission of the International Intestinal Failure Registry (IIFR) is to provide the international intestinal rehabilitation and transplant community with accurate data on the outcomes and course of intestinal failure to support research, quality improvement, and policy development. https://tts.org/irta-registries/irta-ifr2. NCT05241444 is the first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of CD4^LVFOXP3 in up to 36 evaluable human participants with IPEX and evaluate the impact of the CD4^LVFOXP3 infusion on the disease.3. Stanford's local Intestinal Failure Registry (SIFR) ensures ongoing assessment and improvement of intestinal failure outcomes and care provided at Stanford in collaboratiton with the Division of Pediatric Surgery. This registry focuses on clinical outcomes and social developmental outcomes for patients with short bowel syndrome, pediatric CODEs, and pseudoobstruction.4. Multiple, multicenter projects with NASPGHAN (https://naspghan.org/) Nutrition Committee's and the NASPGHAN Intestinal Rehabilitation Special Interest Group ensure assessment of blenderized tube feeding, iron in intestinal failure, and other multicenter research.5. Through the Office of Child Health Equity, I collaborate with the subgroup focusing on equity analytics & community based participatory research as assistant director of health policy to advocate for communities and a world where healthcare and life outcomes are equitable and just. My interests include civic health & disability justice.
A Feasibility Study to Evaluate Safety & Benefit of Eclipse XL1 System in Adult Patients With SBS
The Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System in
Adult Patients with Short Bowel Syndrome shall enroll up to 5 Subjects at up to 2 study sites
in the United States.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
View full details
CD4^LVFOXP3 in Participants With IPEX
This first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing
and the safety of the administration of CD4^LVFOXP3 in up to 36 evaluable human participants
with IPEX and evaluate the impact of the CD4^LVFOXP3 infusion on the disease.